{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","name":"Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","doi":"10.17605/OSF.IO/VB37N","doi_status":"minted","osf_url":"https://osf.io/vb37n/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_aaaaeaf24e6c425e/chain","content_hash":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a","provenance_passport":{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","submission_id":"87768b3b-a60f-46eb-9d78-1f426b2959f8","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a","persistent_identifiers":{"doi":"10.17605/OSF.IO/VB37N","osf_url":"https://osf.io/vb37n/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_aaaaeaf24e6c425e","dw_chain_url":"https://provenance.researka.org/artifacts/claim_aaaaeaf24e6c425e/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","object_type":"publication","parent_object_id":"87768b3b-a60f-46eb-9d78-1f426b2959f8","title":"Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","body_markdown":"**Selected angle:** `source`\n\n## One-sentence thesis\n\nThe cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; patients with type 2 diabetes and established CV disease or CV risk factors. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.\n\n## Evidence Landscape\n\n_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._\n\n**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?\n\n## Evidence receipts\n\n- `fact_id=161900` (`A_core`) — Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%) source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit\n- `fact_id=158054` (`A_core`) — Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo source=Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or O\n- `fact_id=100298` (`A_core`) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) doi=10.1111/obr.13792\n- `fact_id=140867` (`A_core`) — fewer first major adverse CV events with semaglutide vs. placebo, with HRs of 0.74 (95% CI 0.58-0.95) doi=10.3389/fendo.2021.645566\n- `fact_id=137451` (`A_core`) — Compared with placebo, the use of semaglutide was associated with substantial decreases in long-term relative (WMD -12.1%, 95% CI -13.5 to -10.7) and absolute body weight doi=10.1016/j.amjcard.2024.04.041\n\n## Context receipts\n\n_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._\n\n- `fact_id=75386` (`A_core`) — a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) doi=10.2337/dc24-0491\n\n## What this changes\n\n_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.\n- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- `fact_id=100298` (`A_core`) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) Source: Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—\n","metadata":{"abstract":"The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":2,"primary_like_count":3,"year_start":2021,"year_end":2024},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","integrity":null,"doi":"10.17605/OSF.IO/VB37N","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"vb37n","osf_url":"https://osf.io/vb37n/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"vb37n","url":"https://osf.io/vb37n/","doi":"10.17605/OSF.IO/VB37N"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_aaaaeaf24e6c425e","dw_chain_url":"https://provenance.researka.org/artifacts/claim_aaaaeaf24e6c425e/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_aaaaeaf24e6c425e/chain","dw_source_artifact_id":"source_945bebcc13614e97","dw_input_artifact_ids":["source_cf134ad7f7954ab8","source_73a6d67bdb7c430e","source_c26f9dfaa815452d","source_7f130a3324d4492b","source_58ff21b253ec466e","source_8a388d116d104f9a"],"dw_step_id":"step_c77ce7735adf457f","dw_step_hash":"b72c3fa1d73f7f4961ea667a5adfd65992f78baeddac2a3e15ba42692510d35a","dw_status":"registered","content_hash":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a","sha256":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a"},"created_at":"2026-06-05T02:16:41.951962+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_3","claim":"The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; patients with type 2 diabetes and established CV disease or CV risk factors. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_4","claim":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_5","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_6","claim":"`fact_id=137451` (`A_core`) — Compared with placebo, the use of semaglutide was associated with substantial decreases in long-term relative (WMD -12.1%, 95% CI -13.5 to -10.7) and absolute body weight doi=10.1016/j.amjcard.2024.04.041","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_7","claim":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]},{"claim_id":"claim_8","claim":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","url":null},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","content_hash":"sha256:620863b04e6e871c8f4835c6ed3473c871a033ea7628b48fbfbd81ddc430650a","nodes":[{"id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","type":"publication","title":"Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; patients with overweight or obesity without diabetes mellitus; patients with type 2 diabetes and established CV disease or CV risk factors. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim."},{"id":"claim_4","type":"claim","text":"_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._"},{"id":"claim_5","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_6","type":"claim","text":"`fact_id=137451` (`A_core`) — Compared with placebo, the use of semaglutide was associated with substantial decreases in long-term relative (WMD -12.1%, 95% CI -13.5 to -10.7) and absolute body weight doi=10.1016/j.amjcard.2024.04.041"},{"id":"claim_7","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_8","type":"claim","text":"_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._"},{"id":"source_1","type":"source","study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","year":2021,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","year":2024,"doi":"10.1111/obr.13792","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","year":2021,"doi":"10.3389/fendo.2021.645566","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","year":2024,"doi":"10.1016/j.amjcard.2024.04.041","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_1","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_2","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_3","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_4","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_5","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_6","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_7","type":"contains_claim"},{"from":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","to":"claim_8","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nEffect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEfficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nCardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nLong-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"347a8b09-fb77-4dd7-9fa6-eb1d0c767f9f","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6","doi":"10.3389/fendo.2021.645566","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","doi":"10.1016/j.amjcard.2024.04.041","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}